 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis |
| Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim, |
|
DOI: https://doi.org/10.5217/ir.2022.00007 |
|
Biologics for the treatment of moderate- to-severe ulcerative colitis in pediatric patients Pediatric Health, Medicine and Therapeutics. 2012;51  Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology. 2014;146(1):e14-e15 PGI18 COST-EFFECTIVENESS OF BIOLOGICS FOR MODERATE TO SEVERE ULCERATIVE COLITIS IN BRAZIL Value in Health. 2020;23:S146 Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics The Korean Journal of Gastroenterology. 2018;71(4):192 Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Alimentary Pharmacology & Therapeutics. 2018;47(4):539-540 Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab Crohn's Disease and Ulcerative Colitis. 2017;429-433 Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis Journal of Crohn's and Colitis. 2021;15(10):1774-1774 Sa1029 – Cost-Effectiveness of First-Line Biologics for the Management of Moderate-To-Severe Ulcerative Colitis Gastroenterology. 2019;156(6):S-260-S-261 Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab Therapeutics and Clinical Risk Management. 2013;451 A99 COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS Journal of the Canadian Association of Gastroenterology. 2019;2(Supplement_2):197-198 |
